Introduction

Novo Nordisk has paused two additional late-stage tests of its experimental cardiovascular candidate ziltivekimab, following a disappointing result in a prior study. The moves underscore the challenges the Danish pharma giant faces in expanding beyond its dominant obesity and diabetes portfolio.

What Happened

On September 7, 2026, Reuters confirmed that Novo Nordisk halted two heart-failure trials testing ziltivekimab. The decision came after an independent data monitoring committee concluded there was a low probability the studies would show different outcomes from an earlier failed trial. The company will continue a single remaining study focused on patients recovering from a heart attack, with results expected in the first half of 2027. This latest halt follows a July announcement that the same drug missed its primary endpoint for reducing major adverse cardiovascular events.

Why This Matters

The consecutive trial cancellations shrink Novo's cardiovascular diversification plans and increase its reliance on the blockbuster obesity and diabetes franchise. With Eli Lilly aggressively competing in the GLP-1 space, investors are watching how Novo maintains growth momentum without a robust pipeline outside its core markets. Hedge fund data also reflects shifting sentiment, as Novo's fund count rose modestly while Eli Lilly's holdings surged in value and number.

Key Takeaways

  • Novo Nordisk stopped two heart-failure ziltivekimab trials after a monitoring committee found little chance of success
  • The company will continue one heart-attack recovery study, results due in the first half of 2027
  • Core obesity and diabetes business, led by oral Wegovy, remains the primary growth engine
  • Pipeline setbacks increase dependence on existing GLP-1 products amid stiff Eli Lilly competition
  • Hedge fund activity shows modest confidence in Novo versus strong momentum for Lilly

Conclusion

Novo Nordisk's latest trial halts reflect the difficulty of translating its obesity success into other therapeutic areas. While one ziltivekimab study remains ongoing, the shrinking pipeline signals that the company's near-term growth strategy remains tightly focused on its GLP-1 franchise. Investors should monitor the heart-attack trial and broader pipeline developments as key catalysts for the stock's trajectory.